ReleaseWire Connect

Implantable port devices have common application in various treatments such as cancer chemotherapy, chronic illness, parenteral nutrition, pain management etc. among others. Hence, increasing prevalence of these diseases is anticipated to bolster the growth of the implantable port devices market. According to the American cancer society, the cancer survivor population is projected to increase to 30 Mn by 2026. Moreover, growing prevalence of chronic obstructive pulmonary disease (COPD) and diabetes is another factor driving the demand for implantable port devices across the globe. The lower chances of infections in implantable ports and rapid new product development in Implantable Port Devices Market is anticipated to show higher growth rates. Nevertheless, availability of substitute products and the adverse effect associated with implantable port devices such as blocked lines and blood clots in port are the major factors restraining the growth of the global implantable port devices market.

Increased healthcare spending coupled with the growing population with glaucoma, and patients undergoing cataract surgery are anticipated to be the major driving factors for the micro-bypass systems market over the forecast period. The growing number of people suffering from glaucoma is indirectly anticipated to propel the demand for the micro-bypass market. Besides, increasing number of people to opt out rom glasses use is also anticipated to drive the market for micro-bypass system. Increasing clinical trials in the United States using micro-bypass system implants in treating various eye defects, and recently food and drug administration (FDA) for approved one of kind micro-bypass systems implant for the U.S. market is anticipated to be the major driving factor for the Micro-bypass Systems Market over the forecast period. However, the high costs associated with micro-bypass system implant procedures and limited choice of products are restraining the growth of the global micro-bypass systems market.

Renovascular hypertension can be defined as high blood pressure caused by renal artery diseases mainly due to the narrowing of the renal artery. Renal artery diseases, such as renal artery stenosis, result in reduced blood flow due to the narrowing of the artery that provides blood to the kidney. When the kidney receives low blood flow, it responds by releasing hormones that stimulate the body to retain sodium and water as the blood pressure goes up. Major causes of renovascular hypertension are renal artery stenosis, atherosclerosis and fibromuscular dysplasia. Renovascular hypertension is hard to diagnose and generally has no signs or symptoms. Renal hypertension can cause chronic kidney disease. At the beginning of renovascular hypertension treatment, medications are given to control high blood pressure. Antihypertensive drug therapy is given for Renovascular Hypertension Treatment Market.

Fact.MR has announced the addition of the “Endoscopic Balloon Dilator Market Forecast, Trend Analysis & Competition Tracking - Global Review 2018 to 2028"report to their offering.

Tracheostomy trays are specially designed trays, inclusive of all the essential wound dressing components for the management and treatment of tracheostomized patients. A tracheostomy tray comprises an inner cannula which is disposable. Tracheostomy trays are ready to use as they are sterilized at the time of packing only. Tracheostomy Tray Market consist of nitrile gloves, trach brush, drape, twill tape roll, cotton tip applicators, pipe cleaners, gauze sponges, removable basin, retractor, dilator, scalpel knife- handle for surgical blade, artery forceps, scissors, needle holder, blunt hook retractor, dressing forceps, etc. Tracheostomy trays offer great convenience and rapid access to wound care items, as tracheostomy is also performed in case of an emergency and trauma. Tracheostomy is a surgical procedure which involves creating a hole through a patient's trachea (windpipe). The tracheostomy procedure allows the passage of air when the common breathing pathway is obstructed or damaged. A tracheostomy is frequently performed when there is obstruction in the upper airways of the respiratory tract, impaired respiratory function, or cleaning secretions from the upper respiratory airway. The most common conditions that require emergency tracheostomy include upper airway obstruction after accidents, gastrointestinal bleeding, inhalation of smoke at fire incidences, etc.

The growing prevalence of the idiopathic disorder is expected to be the major factor driving the growth of the retroperitoneal fibrosis treatment market over the forecast period. Increasing incidence of diseases associated with drugs, radiation therapy and trauma is expected to boost the growth of Retroperitoneal Fibrosis Treatment Market. Private and public healthcare organizations are taking initiative for the management of rare diseases, which is expected to spur the growth of the retroperitoneal fibrosis treatment market.

Cardiovascular pledgets are the primary choice in various cardiovascular surgeries due to their suturability and handling. Cardiovascular pledgets offer greater feasibility in suturing during surgery. Increased prevalence of various cardiovascular diseases in general population is anticipated to be the major driving factor for the Cardiovascular Pledgets Market. Both synthetic and non-synthetic cardiovascular pledgets are anticipated to exhibit constant growth. Increasing cases of surgical procedures related to heartache are anticipated to propel the growth of the cardiovascular pledgets market. Increasing number of children born with ventricular septal disease and arterial septal disease will also create new opportunities for the cardiovascular pledgets market. Technological advancements in developed countries and growing awareness about pledgets in developed countries is estimated to propel the growth of the cardiovascular pledgets market. However, lack of awareness about pledgets in cardiac healthcare management and high cost associated with pledgets are the two factors anticipated to act as restraining factors for the cardiovascular pledgets market.

The global myrrh gum market is anticipated to gain a significant market share in pharmaceuticals industry over the forecast period, and the Global Myrrh Gum Market is expected to register a single-digit compound annual growth rate (CAGR) from 2018 to 2028. The market across the globe has grown considerably owing to the rising demand for beauty and personal care products, which is expected to increase the manufacturing and sales of myrrh gum globally. The global myrrh gum market in developed economies such as the U.S., Germany, UK and France are expected to be driven by various growth factors such as the presence of key prominent manufacturers and highly classified manufacturing facilities. However, the myrrh gum market is expected to exhibit robust growth in developing countries, such as China, India, Mexico, and the Middle East & African countries.

Dual therapy stent is a coronary artery stent that is based on the combined engineering of biotechnology, and drug-eluting stents to perform functions such as accelerated vessel healing and inhibits cell proliferation. Dual therapy stent is considered as next-generation stents. Drug-eluting stent is constructed through the addition of bone marrow-derived CD34þ endothelial progenitor cell capture system on the luminal stent surface. This technology of dual therapy stent enables them to elute either cytostatic drugs such as everolimus, sirolimus, and zotarolimus or cytotoxic drugs such as paclitaxel which aids in inhibiting of migration and proliferation of vascular smooth muscle cells and restenosis. Dual therapy stent is advantageous as compared to drug-eluting stents and bare metal stents as they offer lower rates of in-stent restenosis, and requires subsequent medical interventions. Dual therapy stent is a combination of an abluminal biodegradable drug-eluting coating and a luminal layer. This advancement modification results in attraction of circulating endothelial progenitor cells which can self-differentiate into endothelium cells. The first dual therapy stent is generated by an additional coating of anti-CD34 antibodies restricted on stent platform to improve deprived endothelialization coupled with drug-eluting stents. This results in binding of antibodies to the CD34 membrane and expressed on cell surface of endothelial progenitor cells to endorse coronary vascular repair process and lowers neointimal hyperplasia.

Fact.MR has announced the addition of the “Cytomegalovirus Assay Market Forecast, Trend Analysis & Competition Tracking - Global Review 2017 to 2027"report to their offering.